Search

Displaying results 2501 - 2510 of 10000 in total
  1. Drug

    Flurpiridaz F-18

    go.drugbank.com/drugs/DB18773
    Approved

    [A264519] Flurpiridaz F-18 is an analog of pyridaben, a mitochondrial complex 1 (MC-1) inhibitor.[L51659] … Flurpiridaz F-18 is a radioactive diagnostic drug indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI), which is an imaging process used in patients with known or suspected

  2. Target

    Vitamin K epoxide reductase complex subunit 1-like protein 1

    go.drugbank.com/bio_entities/BE0002329
    TargetHumans

    Involved in vitamin K metabolism. Can reduce inactive vitamin K 2,3-epoxide to active vitamin K, and may contribute to vitamin K-mediated protection against oxidative stress. Plays a role in vitamin K-dependent gamma-carboxylation of Glu...

    Polypeptides: Vitamin K epoxide reductase complex subunit 1-like protein 1
  3. Target

    Insulin-like growth factor-binding protein complex acid labile subunit

    go.drugbank.com/bio_entities/BE0009058
    TargetCarrierHumans

    Involved in protein-protein interactions that result in protein complexes, receptor-ligand binding or cell adhesion

    Polypeptides: Insulin-like growth factor-binding protein complex acid labile subunit
  4. Drug

    Streptococcus pneumoniae type 19a capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10337
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.

    Mixtures: PNEUMOVAX 23 0,5 ML ENJEKSIYONLUK COZELTI ICEREN FLAKON, 1 ADET, Prevnar 20
  5. Drug

    PTI-801

    go.drugbank.com/drugs/DB05300
    Investigational

    It is a combination of oxycodone with ultralow-dose naltrexone, an opioid antagonist. … PTI-801 represents a new class of drugs to treat pain. PTI-801 can minimize the opioid tolerance, dependence or addiction that is often associated with repeat use of oxycodone.

  6. Drug

    Betaine

    go.drugbank.com/drugs/DB06756
    ApprovedInvestigationalNutraceutical

    [A252235,A252240] Homocystinuria is an inherited disorder that leads to the accumulation of homocysteine in plasma and urine. … Betaine is a methyl group donor that functions in the normal metabolic cycle of methionine.

    Mixtures: EnlSynonyms: TMG, 2-N,N,N-trimethylammonio acetate
  7. Drug

    Dinutuximab

    go.drugbank.com/drugs/DB09077
    ApprovedInvestigational

    It is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk … restricted expression on normal tissues.

  8. Drug

    Etrasimod

    go.drugbank.com/drugs/DB14766
    ApprovedInvestigational

    efficacy of a 2-mg daily dose regimen of etrasimod, with a 32% and 26% remission rate observed in UC 52 and UC 12 trials respectively. … [L48501] The European Commission also approved the marketing of etrasimod on February 19, 2024.[L50998]

  9. Drug

    Vilanterol

    go.drugbank.com/drugs/DB09082
    ApprovedInvestigational

    [L46481,L44461,L44456] BREO ELLIPTA is the first vilanterol-containing product to be approved by the FDA in May 2013, followed by ANORO ELLIPTA in December 2013 and TRELEGY ELLIPTA in September 2020. … Increases in cyclic AMP are associated with the relaxation of bronchial smooth muscle and inhibition of the release of hypersensitivity mediators from mast cells in the lungs.

    Mixtures: TRELEGY ELLİPTA 100 MCG + 62,5 MCG +25 MCG KULLANIMA HAZIR İNHALASYON TOZU, 30 DOZ, ANORO ELLIPTA 62.5 MCG + 25 MCG KULLANIMA HAZIR INHALASYON TOZU, 30 DOZ
  10. Drug

    Protein C

    go.drugbank.com/drugs/DB11312
    ApprovedInvestigational

    It is converted by the thrombin/thrombomodulin-complex on the endothelial cell surface to Activated Protein C (APC). … Once in its activated form, APC functions as a serine protease with potent anticoagulant effects, especially in the presence of its cofactor protein S.

    Mixtures: COFACT 250 IU/10 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADET, COFACT 500 IU/20 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADET